September 21st 2023
Two doses of CD40HVac, a therapeutic vaccine targeting dendritic cells, are being evaluated as treatment for HPV-positive oropharyngeal cancer in a phase 1/2a trial.
September 11th 2023
Patients with heavily pretreated head and neck cancer achieved an overall response rate of 24% with enfortumab vedotin in the phase 2 EV-202 study.
August 25th 2023
A coprimary end point in the phase 3 LEAP-010 study will not be met.
August 9th 2023
The FDA has approved avasopasem for patients with head and neck cancer to treat their radiotherapy-induced severe oral mucositis.
July 15th 2023
The phase 1b/2 ASP-1929-181 continues to investigate the photoimmunotherapy, ASP-1929, in combination with anti-EGFR therapy in patients with advanced head and neck cancer and other solid tumors.
2 Clarke Drive Cranbury, NJ 08512